Victorian Liver Toxicity Alert: Six Hospitalised After Counterfeit Retatrutide
Victoria's Chief Health Officer issues urgent health alert after six patients develop acute liver toxicity from unapproved peptide product labelled as retatrutide.
Victoria’s Chief Health Officer issued an urgent health alert on 20 June 2026 after the Department of Health identified six cases of acute liver toxicity linked to an unapproved peptide product labelled as retatrutide.
The alert, reported by ABC News on 19 June, followed weeks of hospital admissions at Melbourne’s Austin Hospital and Royal Melbourne Hospital. Doctors at both facilities confirmed multiple patients had developed life-threatening liver damage after injecting substances sold as the experimental weight-loss compound.
What is retatrutide?
Retatrutide is a triple-agonist peptide developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously. The compound remains in Phase III clinical trials and has not been approved by any regulatory authority worldwide, including the US Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA).
Despite its unapproved status, retatrutide has gained significant traction on social media platforms including TikTok and Instagram, where users discuss it under the shortened name “reta” and claim it offers faster weight loss than approved GLP-1 medications such as semaglutide and tirzepatide.
The Victorian cases
Among the six documented cases, one patient’s account illustrates the supply chain risk. Megan Hancocks, 32, told the ABC she purchased a product labelled as retatrutide from a beautician during a beauty appointment in late 2025. The clinician reportedly offered off-market peptides sourced from a Chinese manufacturer, sold for cash without medical oversight.
Ms Hancocks took her first dose on 24 December 2025 and a second on 28 December. Within a week she presented to hospital in acute liver failure. Symptoms included extreme jaundice, nausea, vomiting, severe constipation, stomach swelling, and extreme fatigue. She spent approximately one month at the Royal Melbourne Hospital, where her medical team discussed the possibility of a liver transplant.
Six months on, Ms Hancocks remains on steroids for liver repair, has been hospitalised multiple times, and is unable to work. Liver transplant specialist Dr Marie Sinclair from the Victorian Liver Transplant Unit at the Austin Hospital confirmed she had seen and heard of additional patients presenting with similar symptoms after taking products labelled as retatrutide.
What doctors are saying
Senior physicians have told the ABC that any product sold as retatrutide outside a clinical trial is a counterfeit or unregulated knock-off. The substances may contain incorrect dosages, undisclosed ingredients, or contaminants that cause organ damage.
Dr Sinclair’s unit is currently testing vials purchased online by a patient in her 20s who presented to the Austin in acute liver failure after obtaining the product on a gym recommendation.
TGA position
The TGA has not approved retatrutide for therapeutic use in Australia. The compound is not listed on the Australian Register of Therapeutic Goods (ARTG), meaning any product sold under its name in Australia is by definition unapproved and illegal to supply.
The TGA has announced a broader crackdown on unregulated peptides amid rising public health concerns. Products marketed for weight loss, anti-ageing, or performance enhancement that are not on the ARTG may be subject to enforcement action including seizure, infringement notices, and prosecution.
What researchers should know
For Australian researchers, the cases underscore the risks associated with unregulated supply chains. Products sourced from non-accredited manufacturers may not contain the stated compound, may be contaminated, and lack certificates of analysis from NATA-accredited laboratories.
Institutional procurement policies that require vendor qualification, batch-level COAs, and NATA accreditation exist precisely to mitigate these risks. The Victorian cases demonstrate what happens when those safeguards are absent.
Sources
- ABC News, “Warning issued over counterfeit weight-loss drugs labelled as retatrutide,” 19 June 2026
- ABC News, “WA needle exchanges raise concerns over ‘dramatic’ rise in injectable peptide use,” 14 June 2026
- Victorian Department of Health, Chief Health Officer Health Alert, 20 June 2026
- Pharmabiz, “TGA raises concerns over presence of unapproved peptide products in the market,” 20 June 2026
For educational purposes only. This content is informational and reflects publicly reported developments. It is not legal, medical, or regulatory advice. Consult a qualified professional for compliance questions.